ストックスクリーナーアプリを入手
10.19
0.78%
-0.08
プレマーケット:
10.20
0.010
+0.10%
Urogen Pharma Ltd (URGN) 最新ニュース
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC - MarketBeat
UroGen Pharma Reveals Promising Developments in Latest 8-K Filing - Defense World
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral Capital - MarketBeat
UroGen's UGN-102 shows high response in bladder cancer study By Investing.com - Investing.com South Africa
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - BioSpace
UroGen's UGN-102 shows high response in bladder cancer study - Investing.com
UroGen's Bladder Cancer Drug Shows 82% Response Rate in Phase 3 Trial, Aims for FDA First - StockTitan
Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - Simply Wall St
UroGen Pharma Highlights RTGel® Platform and Growth Plans - TipRanks
Jane Street Group LLC Sells 8,198 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
How To Trade (URGN) - Stock Traders Daily
Geode Capital Management LLC Purchases 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Brokerages - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by State Street Corp - Defense World
Fmr LLC Buys 19,670 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN stock touches 52-week low at $10.6 amid market challenges - Investing.com Canada
URGN stock touches 52-week low at $10.6 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70 - MarketBeat
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
(URGN) Investment Report - Stock Traders Daily
UroGen Pharma Grants 112,800 RSUs to Expand Commercial Team for Jelmyto Rollout - StockTitan
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Urogen Pharma Ltd. Announces Long-Term Follow-Up Study to the Olympus Trial Presented At SUO 2024 - Marketscreener.com
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
URGN (UroGen Pharma) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma Ltd. (NASDAQ:URGN) Holdings Raised by RTW Investments LP - MarketBeat
Parkman Healthcare Partners LLC Has $4.41 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade - Yahoo Finance
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - BioSpace
UroGen Pharma Unveils Key Clinical Data for Cancer Treatment Pipeline at SUO 2024 - StockTitan
URGN (UroGen Pharma) Shares Outstanding (EOP) : 42.19 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Shares Outstanding (EOP) : 36.13 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) PE Ratio without NRI : At Loss (As of Dec. 01, 2024) - GuruFocus.com
Vestal Point Capital LP Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment - Clinical Trials Arena
Financial Review: UroGen Pharma (NASDAQ:URGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World
Great Point Partners LLC Has $9.64 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
JELMYTO shows long-term efficacy in UTUC study - Investing.com India
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire
URGN (UroGen Pharma) GF Value Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Momentum Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St
RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com
Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com
Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com
RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com
4.81%
大文字化:
|
ボリューム (24 時間):